Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18145177 | 0.97 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL5465232 | 0.94 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL551724 | 0.91 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL26122620 | 0.82 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL25393445 | 0.78 | — | — | |
| SCHEMBL221478 | 0.75 | — | — | |
| SCHEMBL22682851 | 0.75 | — | — | |
| SCHEMBL24253 | 0.71 | — | — | |
| SCHEMBL7195167 | 0.71 | — | — | |
| SCHEMBL10038449 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4327886-A2 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | Libertas Bio, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3392252-B1 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | LIBERTAS BIO INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20200190095-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ABS DEVELOPMENT 1, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10647720-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | Asan BioSciences, LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-10294212-B2 | Inhibitors of the kynurenine pathway | CURADEV PHARMA, PVT. LTD. (IN) | 2019-05-21 | — | — | US | disclosed |
| US-20190092779-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | Libertas Bio, Inc. | 2019-03-28 | — | — | US | disclosed |
| EP-3216793-B1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2019-03-27 | — | — | EP | disclosed |
| US-20190070182-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | ASANA BIOSCIENCES, LLC | 2019-03-07 | — | — | US | disclosed |
| US-10188654-B2 | Uses of pyrimido-pyridazinones to treat cancer | ASANA BIOSCIENCES, LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-10183944-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ASANA BIOSCIENCES, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ENDO PHARMACEUTICALS INC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130005723-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2013-01-03 | — | — | US | disclosed |
| US-8217036-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2012-07-10 | — | — | US | disclosed |
| US-8039469-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2011-10-18 | — | — | US | disclosed |
| EP-2300483-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | Wyeth LLC (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2294072-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | Wyeth LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20090304692-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | WYETH (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090291079-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009143317-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009143313-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183944-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | THPO, TYMP, TYMS | ALDH1A1 367/4885 |
| US-20090291079-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | MTOR, PIK3CA, PIK3R3 | ALDH1A1 4809/4885 |
| US-20130005723-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | ALDH1A1 4096/4885 |
| US-10294212-B2 | Inhibitors of the kynurenine pathway | IDO1, IDO2, KYNU | ALDH1A1 909/4885 |
| US-20190070182-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | MKI67, DPYD, TYMP | ALDH1A1 146/4885 |
| US-20090304692-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | MTOR, PIK3CA, PIK3R3 | ALDH1A1 4809/4885 |
| US-10188654-B2 | Uses of pyrimido-pyridazinones to treat cancer | MKI67, DPYD, TYMP | ALDH1A1 146/4885 |
| US-20190092779-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | ALDH1A1 367/4885 |
| US-20200190095-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | ALDH1A1 367/4885 |
| US-10647720-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | THPO, TYMP, TYMS | ALDH1A1 367/4885 |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | ALDH1A1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.